Key RNAi Drugs in the Clinic | GenomeWeb

Key RNAi Drugs in the Clinic

Premium

Having had over a decade to mature, the RNAi drugs industry has more therapeutic candidates in clinical development than ever, testing in humans agents that incorporate a variety of designs, modifications, and delivery strategies.

Below is a list of the key RNAi-based therapies currently under active development, broken down by their developer.

Alnylam Pharmaceuticals

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Nuffield Council on Bioethics identifies ethical questions to explore surrounding genome editing.

In a blog post, Brigham and Women's Hospital's Robert Green discusses "predispositional personal genome sequencing."

Stat News reports that there's muted opposition to the Kuwaiti DNA database law.

In Science this week: global genetic diversity map, and more.